1. US Federal Drug Administration. FDA approves first drug for reducing the risk of sexually acquired HIV infection 2012 [Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm312210.htm.
2. Fauci AS, Redfield RR, Sigounas G, Weahkee MD, Giroir BP. Ending the HIV epidemic: a plan for the United States. JAMA : the Journal of the American Medical Association. 2019;321(9):844–5.
3. Mayer KH, Agwu A, Malebranche D. Barriers to the wider use of pre-exposure Prophylaxis in the United States: a narrative review. Adv Therapy. 2020;37(5):1778–811.
4. Centers for Disease Control and Prevention. Interim guidance for clinicians considering the use of preexposure prophylaxis for the prevention of HIV infection in heterosexually active adults. MMWR Morbidity and mortality weekly report. 2012;61(31):586–9.
5. Centers for Disease Control and Prevention. Pre-exposure prophylaxis for the prevention of HIV infection in the United States—2017 update: a clinical practice guideline. Atlanta: CDC; 2018.